Immunoprotective determinants in friend murine leukemia virus envelope protein. 1998

K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institute of Health, 903 South 4th Street, Hamilton, Montana, 59840, USA.

Several immunological epitopes are known to be located within the Friend murine leukemia virus (F-MuLV) envelope protein, but their relative contributions to protection from Friend virus-induced disease are not known. To determine how expression of various immunological determinants affected protection, mice were immunized with recombinant vaccinia viruses expressing different portions of the F-MuLV envelope protein, and they were then challenged with a lethal dose of Friend virus complex. The disease parameters that were followed in the mice were early viremia, early splenomegaly, and late splenomegaly. Both the N-terminal and C-terminal portions of the F-MuLV gp70 were found to protect against late splenomegaly, the primary clinical sign associated with virus-induced erythroleukemia. However, neither region alone protected against early splenomegaly and early viremia, indicating poor immunological control over early virus replication and spread through the spleen and blood. In contrast, mice immunized with a vaccine expressing the entire F-MuLV envelope protein were protected against all three disease parameters. The results indicated that expression of multiple immunological determinants including both T-helper and B cell epitopes was necessary for full protection.

UI MeSH Term Description Entries
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005622 Friend murine leukemia virus A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice. Friend Virus,Rowson-Parr Virus,Rowson Parr Virus,Virus, Friend,Virus, Rowson-Parr
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D012192 Retroviridae Infections Virus diseases caused by the RETROVIRIDAE. Retrovirus Infections,Infections, Retroviridae,Infections, Retrovirus,XMRV Infection,Xenotropic MuLV-related Virus Infection,Xenotropic Murine Leukemia Virus-related Virus Infection,Infection, Retroviridae,Infection, Retrovirus,Infection, XMRV,Infections, XMRV,Retroviridae Infection,Retrovirus Infection,XMRV Infections,Xenotropic MuLV related Virus Infection,Xenotropic Murine Leukemia Virus related Virus Infection
D013163 Splenomegaly Enlargement of the spleen. Enlarged Spleen,Spleen, Enlarged
D014412 Tumor Virus Infections Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Fibroma, Shope,Papilloma, Shope,Infections, Tumor Virus,Infection, Tumor Virus,Shope Fibroma,Shope Papilloma,Tumor Virus Infection
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
June 2003, Archives of virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
June 1991, Journal of immunology (Baltimore, Md. : 1950),
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
October 1991, Journal of virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
January 1983, Journal of virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
May 1981, Biochemical and biophysical research communications,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
May 1999, Journal of virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
March 2001, Proceedings of the National Academy of Sciences of the United States of America,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
December 1991, Virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
March 1998, Virology,
K J Hasenkrug, and D M Brooks, and M N Robertson, and R V Srinivas, and B Chesebro
April 1993, Journal of virology,
Copied contents to your clipboard!